MedTrace Logo

Stage I Multiple Myeloma Treatment

NCT00733538 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2024-04-12

No results posted yet for this study

Summary

* Assessment of survival without progression of stage I MM in two groups: arm A: simple survey and arm B: administration of Zoledronate.
* Describe different progression's type noticed and define the prognosis factors of a fast evolution.

Conditions

Interventions

DRUG

zometa

patients receiving treatment during their follow-up

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Nice

    lead OTHER

Principal Investigators

  • Jean-Gabriel FUZIBET, PU-PH · service de médecine interne, CHU de Nice

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2009-11-30
Completion
2012-11-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00733538 on ClinicalTrials.gov